New hope for kidney transplant patients facing rejection
NCT ID NCT06744647
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study tests a new drug called ALXN2030 in 45 adults who have had a kidney transplant and are experiencing antibody-mediated rejection (AMR). The goal is to see if the drug can help resolve signs of rejection seen on a kidney biopsy after one year of treatment. Participants will receive either ALXN2030 or a placebo, and their kidney function and safety will be monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Birmingham, Alabama, 35249, United States
-
Research Site
Scottsdale, Arizona, 85259, United States
-
Research Site
Los Angeles, California, 90095, United States
-
Research Site
Orange, California, 92868, United States
-
Research Site
Tampa, Florida, 33606, United States
-
Research Site
Atlanta, Georgia, 30309, United States
-
Research Site
Kansas City, Kansas, 66160, United States
-
Research Site
Ann Arbor, Michigan, 48109, United States
-
Research Site
Detroit, Michigan, 48202, United States
-
Research Site
Livingston, New Jersey, 07039, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
New York, New York, 10029, United States
-
Research Site
New York, New York, 10032, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Cincinnati, Ohio, 45267, United States
-
Research Site
Philadelphia, Pennsylvania, 19140, United States
-
Research Site
Dallas, Texas, 75235, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Richmond, Virginia, 23298, United States
-
Research Site
Seattle, Washington, 98195, United States
-
Research Site
Milwaukee, Wisconsin, 53226, United States
-
Research Site
Botucatu, 18618-687, Brazil
-
Research Site
Campinas, 13083, Brazil
-
Research Site
Porto Alegre, 90020-090, Brazil
-
Research Site
São Paulo, 04038-002, Brazil
-
Research Site
São Paulo, 05403-900, Brazil
-
Research Site
Calgary, Alberta, T2N 1N4, Canada
-
Research Site
Edmonton, Alberta, T6G 2R7, Canada
-
Research Site
Vancouver, British Columbia, V6Z 1Y6, Canada
-
Research Site
London, Ontario, N6A 5A5, Canada
-
Research Site
Toronto, Ontario, M5G 2N2, Canada
-
Research Site
Changsha, 430033, China
-
Research Site
Guangzhou, 510080, China
-
Research Site
Nanning, 530007, China
-
Research Site
Shanghai, 201114, China
-
Research Site
Wuhan, 430030, China
-
Research Site
Xi'an, 710061, China
-
Research Site
Seoul, 02841, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Seoul, 3722, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Barcelona, 8003, Spain
-
Research Site
Zaragoza, 50009, Spain
-
Research Site
Kaohsiung City, 813, Taiwan
-
Research Site
Kaohsiung City, 833401, Taiwan
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Birmingham, B15 2GW, United Kingdom
-
Research Site
London, NW3 2QG, United Kingdom
-
Research Site
London, W12 0HS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion stop the Body's attack on a transplanted kidney?
- Can a new drug combo save failing kidney transplants?
- AI may spot hidden kidney transplant rejection
- A drug given to organ donors may help kidneys work faster after transplant
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Blood test clues could make antifungal dosing safer for transplant patients